Adjuvant Global Health Technology Fund, L.P. 13D and 13G filings for AN2 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-28 7:57 pm Sale |
2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
Adjuvant Global Health Technology Fund, L.P. | 2,373,500 7.900% |
-100,000 (-4.04%) |
Filing |
| 2024-02-09 07:06 am Sale |
2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
Adjuvant Global Health Technology Fund, L.P. | 2,473,500 8.300% |
-123,880 (-4.77%) |
Filing |
| 2023-02-10 4:57 pm Purchase |
2022-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
Adjuvant Global Health Technology Fund, L.P. | 2,597,380 13.400% |
2,597,380 (New Position) |
Filing |